Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study.

Collin M Blakely Anatoly UrismanMatthew A GubensClaire K MulveyGreg M Allen Stephen C ShiboskiJulia K RotowTurja Chakrabarti D Lucas Kerr Jacqueline V Aredo Bianca BacaltosMegan GeeLisa TanKirk D JonesW Patrick DevineRobert C DoebeleDara L Aisner Tejas Patil Erin L Schenk Trever G BivonaJonathan W RiessMelissa ColemanJohannes R KratzDavid M Jablons

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)

-mutated NSCLC did not meet its primary end point for MPR rate. However, neoadjuvant osimertinib did not lead to unanticipated AEs, surgical delays, nor result in a significant unresectability rate.

Keyphrases

epidermal growth factor receptor
advanced non small cell lung cancer
phase ii
rectal cancer
tyrosine kinase
clinical trial
small cell lung cancer
locally advanced
lymph node
open label
randomized controlled trial
double blind
phase iii
placebo controlled
combination therapy
smoking cessation